Time filter

Source Type

Monge-Argiles J.A.,Universitary General Hospital of Alicante | Munoz-Ruiz C.,Universitary General Hospital of Alicante | Pampliega-Perez A.,Universitary General Hospital of Alicante | Gomez-Lopez M.J.,Universitary General Hospital of Alicante | And 5 more authors.
Neurochemical Research | Year: 2011

The study of biomarkers in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) is a technique used with increasing frequency in the early diagnosis of Alzheimers disease (AD). Our objectiv was to gain an own experience while evaluating the reliability, sensitivity, and reproducibility of this technique in Spanish patients. Thirty-seven patients with MCI and twenty-four control subjects were studied by means of AD biomarker analysis in CSF. xMAP Luminex and INNO-BIA Alzbio3 reagents of Innogenetics were used. The study variables assessed were levels of Aβ1-42, T-tau and P-tau181p proteins as well as the ratios of T-tau/Aβ 1-42 and P-tau181p/Aβ1-42. Samples from nineteen patients were examined twice. Intra-class correlation coefficients for the three biomarkers used showed values higher than 0.95. We observed significant differences between the control group and the MCI groups. In the 6 months following lumbar puncture (LP), eleven (29%) patients with MCI developed AD. These patients showed significant lower levels in Aβ1-42 protein (276.35 ± 78 vs. 367.13 ± 123.49, P < 0.03) and higher ratios (T-tau/Aβ1-42 [0.38 ± 0.2 vs. 0.22 ± 0.14, P < 0.01] and P-tau181p/Aβ1-42 [0.27 ± 0.13 vs. 0.16 ± 0.1, P < 0.008]) to those in the same group who remained stable. We obtained similar results to those in the most recent reliable literature with our ROC curves, especially with our P-tau181p values and T-tau/Aβ1-42 ratio in order to differentiate between control and AD groups. Our experience showed that the analysis of CSF-AD biomarkers in patients with MCI is reliable, sensitive and reproducible. In our knowledge, this is the first experience in Spanish patients. © 2011 Springer Science+Business Media, LLC.


Carrera-Quintanar L.,University Miguel Hernández | Lopez-Fuertes M.,University Miguel Hernández | Climent V.,Universitary General Hospital of Alicante | Herranz-Lopez M.,University Miguel Hernández | And 4 more authors.
European Journal of Applied Physiology | Year: 2012

It is well known that exposure to extreme environments, such as in high-mountain expeditions, is associated with increased production of reactive oxygen species and related oxidative damage. However, there is little information concerning antioxidant recovery after this type of expedition. Thus, the aim of this study is to analyze the antioxidant recovery status at sea level of five expert alpinists 4 weeks after climbing Cho-Oyu (8,201m). Body composition, cardiorespiratory capacity, and circulating parameters were almost similar to the values obtained at the beginning of the study. However, the alpinists presented high erythrocyte number, related hemogram values, and ferritin. Sodium, alkaline phosphatase, and y-glutamyl-transferase plasma levels were lower. Concerning oxidative stress, plasma uric acid levels were significantly increased, as well as malondialdehyde and protein carbonyls. Neutrophils displayed significantly higher levels of malondialde-hyde and lower catalase activity. Therefore, these data indicate that the oxidative stress during a high mountain expedition is the most probable cause to explain an incomplete recovery in plasma and neutrophil antioxidant status. © Springer-Verlag 2011.


PubMed | Universitary General Hospital of Alicante
Type: Journal Article | Journal: Neurochemical research | Year: 2011

The study of biomarkers in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) is a technique used with increasing frequency in the early diagnosis of Alzheimers disease (AD). Our objectiv was to gain an own experience while evaluating the reliability, sensitivity, and reproducibility of this technique in Spanish patients. Thirty-seven patients with MCI and twenty-four control subjects were studied by means of AD biomarker analysis in CSF. xMAP Luminex and INNO-BIA Alzbio3 reagents of Innogenetics were used. The study variables assessed were levels of A(1-42), T-tau and P-tau(181p) proteins as well as the ratios of T-tau/A(1-42) and P-tau(181p)/A(1-42). Samples from nineteen patients were examined twice. Intra-class correlation coefficients for the three biomarkers used showed values higher than 0.95. We observed significant differences between the control group and the MCI groups. In the 6 months following lumbar puncture (LP), eleven (29%) patients with MCI developed AD. These patients showed significant lower levels in A(1-42) protein (276.35 78 vs. 367.13 123.49, P < 0.03) and higher ratios (T-tau/A(1-42) [0.38 0.2 vs. 0.22 0.14, P < 0.01] and P-tau(181p)/A(1-42) [0.27 0.13 vs. 0.16 0.1, P < 0.008]) to those in the same group who remained stable. We obtained similar results to those in the most recent reliable literature with our ROC curves, especially with our P-tau(181p) values and T-tau/A(1-42) ratio in order to differentiate between control and AD groups. Our experience showed that the analysis of CSF-AD biomarkers in patients with MCI is reliable, sensitive and reproducible. In our knowledge, this is the first experience in Spanish patients.

Loading Universitary General Hospital of Alicante collaborators
Loading Universitary General Hospital of Alicante collaborators